Register now – A must for all API manufacturers and Market Authorization Holders for all APIs at risk!
Challenges for Manufacturers due to New Approaches from EMA and FDA: Learn About Latest Updates on Nitrosamines in Drug substance and Drug Product with Focus on API-derived Nitrosamines (regulatory update published October 2, 2023). Taros provides a problem-solution approach to support your N-nitrosamine risk assessment and root cause analysis with valid experimental data is presented.
Speakers Dr. Helmut Buschmann (Taros Chemicals), Dr. Ranjit Kulkarni (Taros Chemicals)